Review ArticleNanomedicine applied to translational oncology: A future perspective on cancer treatment
Graphical abstract
This review focuses on nanomedicine aimed at increasing the efficacy of currently available cancer therapies.
The relevant challenges to nanomedicine translation are presented and lie in the real difficulty to reach an advanced multidisciplinary forum for discussion, where not only experts from several field from academia, but also clinicians and professionals from the pharmaceutical/healthcare industries and regulatory bodies can take their part in sharing ideas, issues and unmet needs. The principal challenges that all stakeholders are facing are complex, and will be described in this review with a particular emphasis on scientific and regulatory issues.
Section snippets
Design of nanomaterials for cancer therapeutic applications
The medical use of manufactured nanomaterials in oncology is gaining ground rapidly, with various nano-based products already on the market and many progressing through different stages of the drug discovery pipeline. Nanomaterials designed for cancer therapy can be as diverse as micelles, liposomes, dendrimers, inorganic nanoparticles, carbon nanoparticles and nanotubes, nanodiamonds, nanoemulsions, viral nanocarriers, polymeric or peptide nanoparticles, and solid lipid nanoparticles; they can
Clinically approved nanoparticles for cancer therapy
Among the various types of nanomaterials developed for nanomedicine applications, liposomes and polymer-based nanoformulations constitute the majority of the nanotherapeutics approved for intravenous administration during cancer treatment.57, 58, 59 Liposomes are vesicles with a hydrophilic (polar) cavity surrounded by a bi-layer of amphiphilic phospholipids, whose hydrophobic lipid tails and hydrophilic phosphate heads drive self-assembly in water.60 Polymeric nanoparticles are another major
Nanoparticles under clinical evaluation for cancer therapy
A number of cancer nanodrugs are currently in clinical trials, demonstrating both the strong potential of this field and the emerging interest in it. In this section, we describe a few examples of nanomaterials under clinical evaluation for cancer treatment, while a more extensive, though not comprehensive, list is provided in Table 2. Unless specified otherwise, information on clinical-trial phase and status comes from the U.S. National Institutes of Health Clinical Trials Web site (//clinicaltrials.gov/ct2/home
Challenges limiting clinical translation of cancer nanotherapeutics
Despite the huge investments and the astonishing number of scientific publications regarding “nanotechnology for cancer treatment” in the last 10 years (Figure 5), the translation of oncological nanomedicines into clinical practice has been slow compared to that for small-molecule drugs.140, 141 In fact, the majority of nanomaterials designed for clinical use are barely at the stage of in vivo evaluation, and even fewer have reached clinical trials. On the scientific and technological side,
Conclusions
Nanotechnology is a key enabling technology, whose application in medicine ranges from diagnostics to therapeutics to medical devices. As such, it has the potential to provide major health benefits for all. The medical use of manufactured nanomaterials is currently in its infancy, with some anticancer nanomedicines already on the market, but most nanodrugs are still in progress through the different stages of the pharmaceutical pipeline. As is often the case for emerging technologies,
References (171)
- et al.
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Nanomedicine
(2013) - et al.
Nanomaterials for cancer therapy and imaging
Mol Cells
(2011) - et al.
Enabling individualized therapy through nanotechnology
Pharmacol Res
(2010) - et al.
Challenges to effective cancer nanotheranostics
J Control Release
(2012) - et al.
Delivering nanomedicines to patients: a practical guide
Nanomedicine
(2015) - et al.
Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics
Biochim Biophys Acta
(2006) - et al.
Targeting of albumin-embedded paclitaxel nanoparticles to tumors
Nanomedicine
(2009) - et al.
Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions
Biophys J
(2010) - et al.
Emerging nanomaterials for targeting subcellular organelles
Nano Today
(2011) - et al.
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer
Biomaterials
(2008)
Delivery of RNA interference therapeutics using polycation-based nanoparticles
Adv Drug Deliv Rev
Polyethylenimine-based non-viral gene delivery systems
Eur J Pharm Biopharm
The nano-plasma interface: implications of the protein corona
Colloids Surf B: Biointerfaces
Active targeting schemes for nanoparticle systems in cancer therapeutics
Adv Drug Deliv Rev
Blood protein coating of gold nanoparticles as potential tool for organ targeting
Biomaterials
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines
J Control Release
The design and development of DaunoXome® for solid tumor targeting in vivo
Adv Drug Deliv Rev
Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials
J Nanomater
Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes
Int J Immunopharmacol
Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE
J Pharm Sci
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
Ann Oncol
The cellular and molecular basis of hyperthermia
Crit Rev Oncol Hematol
Hyperthermia in combined treatment of cancer
Lancet Oncol
Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress
J Control Release
Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel
J Control Release
Nanotechnology in medicine: from inception to market domination
J Drug Deliv
White Paper to the Horizon 2020 Framework Programme for Research and Innovation — recommendations from the nanomedicine community
Treating metastatic cancer with nanotechnology
Nat Rev Cancer
Cancer nanotechnology: opportunities and challenges
Nat Rev Cancer
Role of nanobiotechnology in the development of personalized medicine
Nanomedicine (Lond)
The upcoming field of theranostic nanomedicine: an overview
J Biomed Nanotechnol
Closing the gap: accelerating the translational process in nanomedicine by proposing standardized characterization techniques
Int J Nanomedicine
FDA and nanotech: baby steps lead to regulatory uncertainty
Dendrimers as biopharmaceuticals: synthesis and properties
Curr Top Med Chem
Quantum dots: an insight and perspective of their biological interaction and how this relates to their relevance for clinical use
Theranostics
Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment
Sci Transl Med
Biomedical applications of functionalized fullerene-based nanomaterials
Int J Nanomedicine
Applications of gold nanoparticles in cancer nanotechnology
Nanotechnol Sci Appl
Nanoshell-enabled photothermal cancer therapy: impending clinical impact
Acc Chem Res
Recent advances and patents on solid lipid nanoparticles
Recent Pat Drug Deliv Formul
Ligand-targeted liposomes for cancer treatment
Curr Drug Deliv
Drug delivery systems: entering the mainstream
Science
Nanomedicine
N Engl J Med
Nanocarriers as an emerging platform for cancer therapy
Nat Nanotechnol
Scope of nanotechnology-based radiation therapy and thermotherapy methods in cancer treatment
Curr Cancer Drug Targets
Delivering nanomedicine to solid tumors
Nat Rev Clin Oncol
Multilayered nanoparticles for personalized medicine: translation into clinical markets
Handbook of Clinical Nanomedicine: From Bench to Bedside
Strategies for advancing cancer nanomedicine
Nat Mater
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Mol Pharm
Mediating tumor targeting efficiency of nanoparticles through design
Nano Lett
Cited by (212)
Recent advances in natural nanoclay for diagnosis and therapy of cancer: A review
2024, Colloids and Surfaces B: BiointerfacesCancer nanomedicine: Recent developments in drug delivery systems and strategies to overcome eventual barriers to achieve a better outcome
2024, Journal of Drug Delivery Science and TechnologyLipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics
2023, Medicine in Drug DiscoveryMagic shotgun over magic bullet for treatment of ovarian cancer via polymeric nanoparticles
2023, Journal of Drug Delivery Science and TechnologyPolysaccharide-based nanoassemblies: From synthesis methodologies and industrial applications to future prospects
2023, Advances in Colloid and Interface ScienceLipid based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application
2023, Journal of Drug Delivery Science and Technology
Funded: This work was partially supported by the EU FP7 NAMDIATREAM project (Contract No. 246479), NANoREG project (Contract No. 310584), MULTIFUN project (Contract No. 262943) and Science Foundation Ireland (Grant No. SFI/12/RC/2278).
Conflict of interest: The authors declare no competing financial interests.